


Claims

1. A compound of formula (I);



5

wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;


R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl;

R² is (CH₂)_mR³ where m is 0 or 1;

10 or R¹ and R² together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R³ is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C₃₋₈ cycloalkyl group, an unsubstituted or substituted straight or branched C₁₋₁₀ alkyl, an unsubstituted or substituted C₅₋₇ cycloalkenyl, R⁵ or R³ is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A:


15



(A)

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, or SO₂Me;

20 R⁵ is



wherein p is 0, 1 or 2, and X is CH₂, O, S, SO or SO₂;

R⁶ is halo, an substituted or unsubstituted (C₁₋₆)alkyl, substituted or unsubstituted (C₃₋₆)cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and R¹⁰ is hydrogen or R¹⁰ is halo, an substituted or unsubstituted (C₁₋₆)alkyl, substituted or unsubstituted (C₃₋₆)cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and R⁶ is hydrogen:

25

R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SOqR⁹;

R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;

R^9 is C_{1-6} alkyl;


R^{12} is hydrogen or C_{1-6} alkyl;

q is 0, 1 or 2;

R_a can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

- 5 R_b can be independently be selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$ or $NHCOOC_{1-6}$ alkyl; or a pharmaceutically acceptable derivative thereof.

- 10 2. A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ia):



wherein;

- 15 R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C_{3-8} cycloalkyl group or a straight or branched C_{1-6} alkyl group;

R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;


R^{12} is hydrogen or C_{1-6} alkyl;

d is 0, 1, 2 or 3;

- 20 m is 0 or 1;

or a pharmaceutically acceptable derivative thereof.

3. A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ib):



wherein;

R^3 is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A;

R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;


- 30 R^{12} is hydrogen or C_{1-6} alkyl;

d is 0, 1, 2 or 3;

m is 0 or 1;

or a pharmaceutically acceptable derivative thereof.

4. A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ic):



5

wherein;

R^1 and R^2 together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

10 R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

R^{12} is hydrogen or C_{1-6} alkyl;

d is 0, 1, 2 or 3;

or a pharmaceutically acceptable derivatives thereof.

15

5. A compound as claimed in Claim 1 selected from Example 1 to 65.

6. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 5 or 2 or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.

20

7. A pharmaceutical composition as claimed in claim 6 further comprising a second therapeutic agent.

8. A pharmaceutical composition as claimed in claim 7 wherein the second therapeutic agent is a PDE4 inhibitor.

25

9. A method of treating a mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof.

30

10. A compound of formula (I) as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof for use as a medicament in the treatment of pain.